

PF-04523655 - Wet AMD Intravitreal

It is a siRNA, 19 nucleotides in length, that inhibits the expression of the hypoxia-inducible gene RTP801.

This stress-response gene mediates the mammalian target of rapamycin (mTOR) pathway.

PF-04523655 has been shown to reduce the volume of choroidal neovascularization in a mouse model.

PF-04523655 has been shown to cause regression of CNV in experimental studies of mice and primates.

Intravitreal small-interfering RNA (siRNA) PF-04523655 (Quark; licensed to Pfizer) used to treat choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) seems to be safe and well tolerated in an interim phase I analysis.

“No adverse events were observed up to the 3,000-μg dose”⁽¹⁰⁾.

[View PDF](#)